Adeno-Associated Viral Vectors and the Retina
There are a variety of diseases of the retina arising from genetic and non-genetic causes, or a combination of both, that lead to the loss of vision. The retina is a prime location for gene therapy because of its accessibility, immune privileged status (Caspi, 2006), and susceptible cell types. Several strategies have been attempted to rescue retinal disease, including gene replacement (Acland et al., 2001), gene knockdown with both ribozymes (Gorbatyuk et al., 2007) and siRNA (Kiang et al., 2005), and therapeutic gene supplementation (Deng et al., 2005).
KeywordsGene Therapy rAAV Vector Ubiquitous Promoter Vitelliform Macular Dystrophy Gene Therapy Experiment
Unable to display preview. Download preview PDF.
- Boulanger, A., Liu, S., Henningsgaard, A.A., Yu,S., and Redmond, T.M. 2000, The upstream region of the Rpe65 gene confers retinal pigment epithelium-specific expression in vivo and in vitro and contains critical octamer and E-box binding sites. J. Biol. Chem. 275: 31274&–31282.PubMedCrossRefGoogle Scholar
- Deng, W.T., Yan, Z., Dinculescu, A., Pang, J., Teusner, J.T., Cortez, N.G. et al. 2005, Adeno-associated virus-mediated expression of vascular endothelial growth factor peptides inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy. Hum. Gene Ther. 16: 1247&–1254.PubMedCrossRefGoogle Scholar
- Huttner, N.A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J.A., Buning, H., and Hallek, M. 2003, Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 10: 2139&–2147.PubMedCrossRefGoogle Scholar
- Jacobson, S.G., Acland, G.M., Aguirre, G.D., Aleman, T.S., Schwartz, S.B., Cideciyan, A.V. et al. 2006a, Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. 13: 1074&–1084.Google Scholar
- Jacobson, S.G., Boye, S.L., Aleman, T.S., Conlon, T.J., Zeiss, C.J., Roman, A.J. et al. 2006b, Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther. 17: 845&–858.Google Scholar
- Muzyczka, N. and Berns, K.I. 2001, Chapter 69, Fields Virology. Lippincott Williams & Wilkins.Google Scholar